However, the absolute NK count was significantly lower in the responder group in the first month (223.4/μl vs. 383.7; p < 0.001) following aHSCT, as were CD4 + TC counts in the first 3 months after aHSCT (77.7/μl vs. 144.6/μl; p < 0.01 and 88.9/μl vs. 142.2/μl; p < 0.05 respectively) and BC at the timepoints 3 and 6 months (115.2/μl vs. 203.6/μl; p < 0.05 and 161.2/μl vs. 303.2/μl; p < 0.01 respectively) after aHSCT (Fig. 1). This evidence concerns the gene CD4 and breast cancer.